Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [916]
News [2627]
Articles [114]
Editorials [3]
Conferences [85]
elearning [27]
FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19...
New addition to standard-of-care treatments for non-small-cell lung cancer patients has potential to increase progression-free survival
New addition to standard-of-care treatments for non-small-cell lung cancer patients has potential to increase...
Combination treatment improves response to immunotherapy for lung cancer
Combination treatment improves response to immunotherapy for lung cancer
New cancer cachexia treatment boosts weight gain and patient activity
New cancer cachexia treatment boosts weight gain and patient activity
WCLC 2024: Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous amivantamab-vmjw
WCLC 2024: Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung...
ESMO 2024: Encoradenib & binimetinib shows long-term clinically meaningful response in patients with BRAF V600E-mutant metastatic non-small Cell lung cancer
ESMO 2024: Encoradenib & binimetinib shows long-term clinically meaningful response in patients with BRAF V600E...
FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
New, rare type of small cell lung cancer identified by research team
New, rare type of small cell lung cancer identified by research team
WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in patients with ROS1+ non-small cell lung cancer
WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation